Use these links to rapidly review the document
Table of Contents

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October 2016

FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrant's name into English)

Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)

        Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
       Form 20-F     ý         Form 40-F     o

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

        Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
       Yes     o                     No     ý

        If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 –               .

Table of Contents

i

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

FINANCIAL INFORMATION

Management's Discussion and Analysis

Forward-looking Statements

       This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). When used in this report, the words "outlook," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are generally intended to identify forward looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated, and future events and actual results, financial and otherwise, could differ materially from those set forth in or contemplated by the forward-looking statements contained elsewhere in this report. We have based these forward-looking statements on current estimates and assumptions made to the best of our knowledge. By their nature, such forward-looking statements involve risks, uncertainties, assumptions and other factors which could cause actual results, including our financial condition and profitability, to differ materially positively or negatively relative to the results expressly or implicitly described in or suggested by these statements. Moreover, forward-looking estimates or predictions derived from third parties' studies or information may prove to be inaccurate. Consequently, we cannot give any assurance regarding the future accuracy of the opinions set forth in this report or the actual occurrence of the projected developments described herein. In addition, even if our future results meet the expectations expressed here, those results may not be indicative of our performance in future periods.

       These risks, uncertainties, assumptions, and other factors that could cause actual results to differ from our projected results include, among others, the following:

•

changes in governmental and commercial insurer reimbursement for our complete products and services portfolio, including the United States ("U.S.") Medicare reimbursement system for dialysis and other health care services;



•

the outcome of government and internal investigations as well as litigation;



•

risks relating to compliance with the government regulations applicable to our business including, in the U.S., the Anti-Kickback Statute, the False Claims Act, the Stark Law, the Health Insurance Portability and Accountability Act, the Health Information Technology for Economic and Clinical Health Act and the Foreign Corrupt Practices Act, the Food, Drug and Cosmetic Act and comparable regulatory regimes in many of the more than 120 countries in which we supply health care services and/or products;



•

the influence of commercial insurers and managed care organizations, including efforts by these organizations to manage costs by limiting healthcare benefits, reducing provider reimbursement and/or restricting options for patient funding of health insurance premiums;



•

the impact of health care reforms and regulation;



•

product liability risks;



•

risks relating to our ability to continue to make acquisitions;



•

the impact of currency fluctuations;

1

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

•

the United Kingdom vote in favor of withdrawal from the European Union and its possible effects on the tax, tax treaty, currency, operational, legal and regulatory regimes to which our businesses in the region are subject, as well as the present uncertainty regarding these and related issues;



•

our ability to protect our information technology systems against cybersecurity attacks or prevent other privacy or data security incidents;



•

changes in utilization patterns for pharmaceuticals and in our costs of purchasing pharmaceuticals;



•

introduction of generic or new pharmaceuticals that compete with our pharmaceutical products;



•

increases in raw material and energy costs or the inability to procure raw materials;



•

collectability of our receivables, which depends primarily on the financial stability and liquidity of our governmental and commercial payors;



•

our ability to achieve cost savings in various health care risk management programs in which we participate or intend to participate; and



•

the greater size, market power and experience of certain competitors in certain geographic regions and business lines.

       Important factors that could contribute to such differences are noted in "Financial Condition and Results of Operations – Overview, legislation and growth – Overview" below, in Note 11 of the Notes to Consolidated Financial Statements (unaudited), "Commitments and Contingencies" included in this report, in Note 19 of the Notes to Consolidated Financial Statements, "Commitments and Contingencies" included in our Annual Report on Form 20-F for the year ended December 31, 2015, and under "Risk Factors" and elsewhere in that report.

       Our business is also subject to other risks and uncertainties that we describe from time to time in our public filings. Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

       Our reported financial condition and results of operations are sensitive to accounting methods, assumptions and estimates that are the basis of our financial statements. The actual accounting policies, the judgments made in the selection and application of these policies and the sensitivities of reported results to changes in accounting policies, assumptions and estimates, are factors to be considered along with our financial statements and the discussion under "Financial Condition and Results of Operations – Results of Operations" below. There have been no significant changes during the nine months ended September 30, 2016 to the items disclosed within the critical accounting policies and estimates in Item 5, "Operating and Financial Review and Prospects – Critical Accounting Policies" in our Annual Report on Form 20-F for the year ended December 31, 2015.

Financial Condition and Results of Operations

       You should read the following discussion and analysis of the results of operations of Fresenius Medical Care AG & Co. KGaA ("FMC-AG & Co. KGaA," or the "Company") and its subsidiaries in conjunction with our unaudited consolidated financial statements and related notes contained elsewhere in this report and our disclosures and discussions in our Annual Report on Form 20-F for the year ended December 31, 2015. The results within this discussion and analysis are unaudited. In this report, "FMC-AG & Co. KGaA," or the "Company," "we," "us" or "our" refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term "North America Segment" refers to our North America operating segment; the term "EMEA Segment" refers to the Europe, Middle East and

2

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Africa operating segment, the term "Asia-Pacific Segment" refers to our Asia-Pacific operating segment, and the term "Latin America Segment" refers to our Latin America operating segment. The term "Corporate" includes certain headquarters' overhead charges, including accounting and finance, centrally managed production, asset management, quality management, procurement and research and development. The term "Constant Currency" or at "Constant Exchange Rates" means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year, as described below under "Non-US GAAP Measures for Presentation – Constant Currency."

Overview, legislation and growth

Overview

       We are the world's largest kidney dialysis company, based on publicly reported sales and number of patients treated and our dialysis product offerings. We provide dialysis care and related services to persons who suffer from end stage renal disease ("ESRD") as well as other health care services. We develop and manufacture a full range of dialysis machines, systems and disposable products, which we sell to customers in more than 120 countries and also use in our internal health care service operations. Our dialysis business is therefore vertically integrated. We describe our other health care services as "Care Coordination." Care Coordination currently includes coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, ambulatory surgery center services and urgent care services, which, together with dialysis care services represent our health care services. We estimated the volume of the global dialysis market was approximately $73 billion in 2015. Dialysis patient growth results from factors such as the aging population and increased life expectancies; shortage of donor organs for kidney transplants; increasing incidence of kidney disease and better treatment of and survival of patients with diabetes, hypertension and other illnesses, which frequently lead to the onset of chronic kidney disease; improvements in treatment quality, which prolong patient life; and improving standards of living in developing countries, which make life-saving dialysis treatment available.

       As a global company delivering health care services and dialysis products, we face the challenge of addressing the needs of a wide variety of stakeholders, such as patients, customers, payors, regulators and legislators in many different economic environments and health care systems. In general, government-funded programs (in some countries in coordination with private insurers) pay for certain health care items and services provided to their citizens. Not all health care systems provide for dialysis treatment. Therefore, the reimbursement systems in various countries and ancillary services utilization environment significantly influence our business.

       The majority of health care services we provide are paid for by governmental institutions. Approximately 32% of our consolidated revenues are attributable to U.S. federally-funded health care benefit programs, such as Medicare and Medicaid reimbursement, under which reimbursement rates are set by the Centers for Medicare & Medicaid Services ("CMS"). Legislative changes could affect Medicare reimbursement rates for a significant portion of the services we provide. To date, while we have generally

3

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

experienced stable reimbursement globally, the stability of reimbursement in the U.S. has been affected by the following legislative developments:

Significant Legislative Impacts on U.S. Reimbursement

•

Under the Medicare Improvements for Patients and Providers Act of 2008 ("MIPPA"), for patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate, ESRD prospective payment system ("ESRD PPS"), to encompass substantially all goods and services provided during the dialysis treatment. MIPPA further created the ESRD quality incentive program ("QIP") which dictates that dialysis facilities that fail to achieve quality standards established by CMS could have payments reduced by up to 2 percent.



•

MIPPA also includes a provision for an annual adjustment to the ESRD PPS base rate based on changes in the costs of a "market basket" of certain health care items and services, less a productivity adjustment.



•

Additionally, as a result of the Budget Control Act of 2011 ("BCA") and subsequent activity in Congress, a $1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect on March 1, 2013 and is expected to continue through mid-2024. In particular, a 2% reduction to Medicare payments took effect on April 1, 2013 and continues in force. Spending cuts pursuant to U.S. Sequestration have adversely affected and will continue to adversely affect our revenues, earnings and cash flows.



•

In 2014, as mandated by American Taxpayer Relief Act of 2012 ("ATRA"), CMS issued a final rule for the ESRD PPS, which phased in payment reductions to account for changes in utilization of certain pharmaceuticals and biologicals that are included in the ESRD PPS, which were subsequently modified by Protecting Access to Medicare Act of 2014 ("PAMA"). These reductions will reduce our market basket inflation adjustment by (1.25%) in 2016 and 2017, and 1% in 2018.



•

On July 7, 2016, CMS issued a proposed rule that, if implemented, would modify certain payment policies, payment rates, and quality provisions in the Physician Fee Schedule for calendar year 2017. The proposed rule includes material decreases in the reimbursement rates for many of the procedures performed routinely by Fresenius Vascular Care. Fresenius Vascular Care and various other interested parties have asked CMS to reconsider the extent of the proposed reimbursement cuts based on various perceived errors in CMS's methodologies for calculating the providers' healthcare delivery costs. CMS is expected to issue a final rule in November 2016. To the extent the rule is implemented as proposed these reimbursement cuts may have a material adverse impact on our revenues, earnings and cash flows.

Significant Administrative Impacts on U.S. Reimbursement

       On November 6, 2015, CMS published a final rule to update payment policies and rates under the ESRD PPS for renal dialysis services furnished on or after January 1, 2016. In this final rule, CMS clarified that once a non-oral version of a previously oral-only drug, such as phosphate binders and calcimimetics, is approved by the Food and Drug Administration ("FDA"), such drug will cease to be considered oral-only. At such time, CMS will commence a process to issue billing codes so that both the oral and non-oral versions of the drug are billable under Part B for a period of at least two years using a transition drug add-on payment adjustment such as average sales price plus 6%, or some other mechanism set in accordance with Section 1847A of the Social Security Act. During this transition period, CMS will not pay outlier payments for these drugs, but will collect data reflecting utilization of both the oral and injectable or intravenous forms of the drugs, as well as payment patterns, in order to more accurately determine the

4

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

appropriate payment rate to be included in the ESRD PPS for these drugs. At the end of this transition period, CMS will add payment for the oral and non-oral versions of the drug into the ESRD PPS through a public rulemaking process similar to that used to set annual ESRD PPS rates. Any failure by CMS to provide adequate additional reimbursement for new drugs or other products that are added to the ESRD PPS could have a material adverse effect on our health care services business and results of operations.

Recent CMS ESRD PPS Payment Rates

       On November 6, 2015, CMS published the final ruling regarding the ESRD PPS rate for 2016. We and other large dialysis organizations will experience a 0.2% increase in payments. The base rate per treatment is $230.39, which represents an approximate reduction of 4%, net, from the 2015 base rate. The 2016 final ruling reflects a net market basket increase of 0.15% (2% less 1.25% PAMA reduction and 0.6% productivity adjustment), application of a wage index budget-neutrality adjustment factor of 1.000495 and application of a refinement budget-neutrality adjustment factor of 0.960319. However, the approximate 4% reduction is almost completely offset with CMS proposed case mix adjustments based upon their analysis of the fiscal years 2012 and 2013.

       On June 30, 2016, CMS published a proposed ruling regarding the ESRD PPS rate for 2017. We and other large dialysis organizations will experience a 0.3% increase in payments as compared to the ESRD PPS rate for 2016. The proposed base rate per treatment is $231.04, which reflects a reduced market basket increase of 0.35%, application of a wage index budget neutrality adjustment factor of 1.0004482 and application of budget-neutrality adjustment factors of 0.999552 and 0.999729. This proposed rule also includes potential changes to the 2019 and 2020 ESRD QIP measures.

Reimbursement Expectation

       As a consequence of the pressure to decrease health care costs, government reimbursement rate increases in the U.S. have historically been limited and are expected to continue in this fashion. We have generally experienced stable reimbursement globally, including the balancing of unfavorable reimbursement changes in certain countries with favorable changes in other countries. In the future, we expect to experience generally stable reimbursements for dialysis services globally. However, any significant decreases in Medicare or commercial reimbursement rates or patient access to commercial insurance plans could have material adverse effects on our health care services business and, because the demand for dialysis products is affected by Medicare reimbursement, on our products business. To the extent that increases in operating costs that are affected by inflation, such as labor and supply costs, are not fully reflected in a compensating increase in reimbursement rates, our business and results of operations may be adversely affected.

Participation in new Medicare Payment Arrangements

       CMS is working with various health care providers to develop, refine and implement innovative models of care for Medicare and Medicaid beneficiaries. The extent to which the long-term operation and evolution of these care models, including Accountable Care Organizations, Bundled Payments for Care Improvement Initiative, the Comprehensive ESRD Care Model ("CEC Model"), which includes the development of ESRD Seamless Care Organizations ("ESCOs") and other models, will impact the health care market over time is uncertain. Our U.S. health care services businesses may choose to participate in certain of these models in certain markets either as a partner with other providers or independently. As existing and new models of care emerge and evolve both in the government and private sectors, patients

5

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

may choose to be treated by or may be assigned by CMS or other insurers to another provider's care organization, which could have a materially adverse effect on our revenues, earnings and cash flow. As discussed below, we are currently participating in certain of these models.

       We participate in CMS's CEC Model, through ESCOs in six markets. The CEC Model seeks to deliver better health outcomes for ESRD patients while lowering Medicare's costs. ESCOs that achieve the program's minimum quality thresholds and generate reductions in CMS's cost of care above certain thresholds for the ESRD patients covered by the ESCO will receive a share of the cost savings. Our ESCOs also share the risk of cost increases above certain thresholds and are required to reimburse CMS for a share of any such increases. The CEC Model commenced on October 1, 2015, and the initial agreement period lasts three years. Thereafter, CMS may offer to extend an ESCO's agreement for an additional two years based on the ESCO's performance. CMS is expanding the CEC Model in 2017 and has requested applications for new ESCOs that would start on January 1, 2017. The Company has applied and is waiting public announcement from CMS of the new ESCO markets.

       The Bundled Payments for Care Improvement ("BPCI") initiative is a CMS three-year pilot initiative through which qualified provider organizations can take financial accountability for all Part A and Part B services, including acute inpatient hospital services, physician services, and post-acute services, furnished to Medicare beneficiaries during an episode of illness or course of treatment that initiates with a hospitalization and continues for 90 days following hospital discharge. Our majority-owned subsidiary, Sound Inpatient Physicians, Inc. ("Sound") commenced participation under BPCI in April 2015 in several markets. Under the BPCI, Sound has the ability to receive additional payments if its physicians are able to deliver quality care at a cost that is lower than certain targets pre-established by CMS, but it also has the risk of incurring financial penalties if episode of care costs are higher than the targets. Should Sound fail to perform as required under its BPCI agreement, CMS may terminate Sound's participation in the BPCI program, in whole or in part.

       We have entered into various arrangements with both government and private sector health care insurers which involve taking risk for the complete care of certain ESRD patients in exchange for set payments. We are currently operating Medicare Advantage ESRD Chronic Special Needs Plan ("MA-CSNP") in three states and will launch on January 1, 2017 new MA-SNPs in two additional states. MA-CSNPs are Medicare Advantage health plans offered by private companies that contract with Medicare to provide patients with Medicare benefits. Enrollment in these plans is limited to special needs individuals with specific severe or disabling chronic conditions, such as ESRD. Our MA-CSNPs provide services, including Care Coordination services, and receive capitated payments from Medicare for the complete care of enrolled ESRD patients. On April 4, 2016, CMS finalized the 2017 payments for Medicare Advantage plans and the Part D Prescription Drug Program. CMS expects a revenue change of 0.85% without consideration for expected growth in coding acuity which typically provides an additional 2.2%.

       We also participate in sub-capitation and other shared savings and risk arrangements with certain Medicare Advantage plans, accountable care organizations and other integrated care organizations under which we assume risk and share in savings realized in providing care to the plans' ESRD patients.

Premium Assistance Programs

       On August 18, 2016, CMS issued a Request for Information ("RFI") seeking public comment on concerns about providers' steering patients inappropriately to individual plans offered on the Patient Protection and Affordable Care Act individual market plans. We and other dialysis providers, commercial

6

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

insurers and other industry participants responded to the RFI, and in that response, we reported that we do not engage in such steering. In the RFI, CMS sought public comments about regulatory changes that, if adopted by CMS, may negatively impact the ability of some of Company's patients to receive charitable assistance to fund their commercial insurance premiums.

Company Structure

       Our operating segments are the North America Segment, the Europe, Middle East and Africa ("EMEA") Segment, the Asia-Pacific Segment and the Latin America Segment. Our management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, our management believes that the most appropriate U.S. GAAP measures are revenue, operating income and operating income margin. We do not include income taxes as we believe this is outside the segments' control. Financing is a corporate function which our segments do not control. Therefore, we do not include interest expense relating to financing as a segment measurement. Similarly, we do not allocate certain costs which relate primarily to certain headquarters' overhead charges, including accounting and finance, because we believe that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement related to production are centrally managed at Corporate. The Company's global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as Corporate activities (See Note 14 of the Notes to Consolidated Financial Statements (unaudited) "Segment and Corporate Information" found elsewhere in this report). Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but accounted for at Corporate. Accordingly, all of these items are excluded from our analysis of segment results and are discussed below in our consolidated results of operations.

7

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

(1) Net of patient service bad debt provision

8

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Three months ended September 30, 2016 compared to three months ended September 30, 2015

(1) For further information on Constant Exchange Rates, see "Non-U.S. GAAP Measures for Presentation – Constant Currency" below.

(2) Net of patient service bad debt provision.

(3) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

       Total Revenue increased by 9% (9% increase at Constant Exchange Rates) to $4,598 million for the three months ended September 30, 2016 from $4,231 million in the same period of 2015 due to increases in Health Care revenue and dialysis product revenue.

       Health Care revenue increased by 10% to $3,734 million (10% increase at Constant Exchange Rates) for the three months ended September 30, 2016 from $3,402 million in the same period of 2015, mainly due to increases in organic revenue per treatment (5%), growth in same market treatments (3%) and contributions from acquisitions (2%).

       Dialysis treatments increased by 5% for the three months ended September 30, 2016 as compared to the same period in 2015. The increase is due to same market treatment growth (3%) and contributions from acquisitions (2%).

9

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

       At September 30, 2016, we owned, operated or managed (excluding those managed but not consolidated in the U.S.) 3,579 dialysis clinics compared to 3,402 dialysis clinics at September 30, 2015. During the three months ended September 30, 2016, we acquired 57 dialysis clinics, opened 31 dialysis clinics and combined or closed 13 clinics. The number of patients treated in dialysis clinics that we own, operate or manage (excluding patients of dialysis clinics managed but not consolidated in the U.S.) increased by 5% to 306,366 at September 30, 2016 from 291,229 at September 30, 2015.

       Dialysis product revenue increased by 4% (5% increase at Constant Exchange Rates) to $864 million as compared to $829 million in the same period of 2015. The increase at Constant Exchange Rates was driven by increased sales of machines, dialyzers, products for acute care treatments, bloodlines as well as hemodialysis solutions and concentrates, partially offset by lower sales of renal pharmaceuticals.

       The decrease in gross profit margin to 32.0% from 32.7% primarily reflects decreases in the North America Segment and the EMEA Segment. The decrease in the North America Segment was mainly due to an unfavorable impact from Care Coordination services and higher personnel expense related to dialysis services, partially offset by lower costs for health care supplies and a favorable impact from a higher volume of dialysis treatments with commercial payors. The decrease in the EMEA Segment was driven by an unfavorable impact from manufacturing costs and an unfavorable impact from foreign exchange.

       Selling, general and administrative ("SG&A") expenses increased to $787 million in the three months ended September 30, 2016 from $742 million in the same period of 2015. SG&A expenses as a percentage of sales decreased to 17.1% for the three months ended September 30, 2016 in comparison with 17.5% in the same period of 2015 due to decreases in the Latin America Segment and a favorable impact of varying margins across our four reporting segments, partially offset by an increase in the North America Segment. The decrease in the Latin America Segment was mainly due to the prior year loss related the divestment of the dialysis service business in Venezuela and the impact from higher revenue in the region, partially offset by unfavorable foreign exchange effects. The increase in the North America Segment was attributable to a cost impact related to the vesting of long term incentive plan grants, an unfavorable impact from Care Coordination services and higher personnel expense, partially offset by lower legal expenses.

       Research and development ("R&D") expenses increased by 26% to $44 million for the three months ended September 30, 2016 from $35 million for the same period of 2015 driven by higher personnel expense.

       Income from equity method investees increased to $29 million for the three months ended September 30, 2016 from $9 million for the same period of 2015. This increase is primarily related to higher income from the Vifor Fresenius Medical Care Renal Pharma Ltd. joint venture due to increased revenue resulting from the expansion of its product portfolio.

       Operating income increased to $670 million for the three months ended September 30, 2016 from $614 million for the same period in 2015. Operating income margin increased to 14.6% for the three months ended September 30, 2016 as compared to 14.5% for the same period in 2015 as a result of decreased SG&A as a percentage of revenue and increased income from equity method investees, partially offset by decreased gross profit margin.

       Delivered EBIT increased to $597 million for the three months ended September 30, 2016 from $530 million for the same period in 2015 as a result of increased operating income, coupled with decreased noncontrolling interests due to a change in how the effects of CMS cost recoveries are recognized in our

10

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

joint ventures involving dialysis clinics and decreased noncontrolling interest expense related to Care Coordination.

       Interest expense increased by 4% to $110 million for the three months ended September 30, 2016 from $106 million for the same period in 2015 due to the higher impact of the valuation of the embedded derivative related to the equity-neutral convertible bonds issued in September 2014 and the related call option on our shares. Interest income increased by 52% to $10 million for the three months ended September 30, 2016 as compared to $6 million for the same period in 2015 due to the higher impact of the valuation of the derivative embedded in the convertible debt and the related call option on our shares as well as interest income related to delayed payments, partially offset by lower interest income due to the repayment of interest bearing notes receivables in the fourth quarter of 2015.

       Income tax expense decreased to $164 million for the three months ended September 30, 2016 as compared to $168 million for the same period in 2015. The effective tax rate decreased to 28.8% from 32.8% for the same period of 2015 mainly driven by lower tax expense as a result of released tax liabilities in the third quarter of 2016 due to tax audit settlements with the tax authorities and a favorable impact from the prior year non-tax deductible loss from the divestment of our dialysis service business in Venezuela, partially offset by a lower portion of tax-free income attributable to noncontrolling interests compared to income before taxes.

       Net income attributable to noncontrolling interests for the three months ended September 30, 2016 decreased to $73 million from $84 million for the same period of 2015 primarily driven by a change in how the effects of CMS cost recoveries are recognized in our joint ventures involving dialysis clinics and decreased noncontrolling interest expense related to Care Coordination.

       Net income attributable to shareholders of FMC-AG & Co. KGaA for the three months ended September 30, 2016 increased by 27% to $333 million from $262 million for the same period in 2015 as a result of the combined effects of the items discussed above. Excluding the 2015 impacts of (i) the after tax loss, $26.9 million, from the divestment of our dialysis service business in Venezuela and (ii) the realized portion of the after tax gain, $4.8 million, from the sale of our European marketing rights for certain renal pharmaceuticals to our joint venture, Vifor Fresenius Medical Care Renal Pharma, net income attributable to FMC KGaA increased by 17%.

       Basic earnings per share increased by 26% for the three months ended September 30, 2016 to $1.09 as compared with $0.86 for the same period in 2015 primarily due to the increase in net income attributable to shareholders of FMC-AG & Co. KGaA described above. The average weighted number of shares outstanding for the period was approximately 306.0 million in 2016 (304.7 million in 2015).

       We employed 108,851 people (full-time equivalents) as of September 30, 2016 compared to 102,591 as of September 30, 2015, an increase of 6%, primarily due to overall growth in our business.

       The following discussions pertain to the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment and the measures we use to manage these segments.

11

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

(1) Net of patient service bad debt provision.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

(3) For further information on these metrics, please refer to the discussion below of our Care Coordination measures under "Care Coordination Business Metrics for Presentation."

(4) The 2016 metric may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

Dialysis

Revenue

       Dialysis revenue increased for the three months ended September 30, 2016 by 6% to $2,682 million from $2,533 million in the same period of 2015.

       Dialysis care revenue increased for the three months ended September 30, 2016 by 6% to $2,450 million from $2,314 million in the same period of 2015. This increase was driven by same market treatment growth (3%), increases in organic revenue per treatment (1%), contributions from acquisitions (1%) and a reduction of bad debt (1%).

12

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

       Dialysis treatments increased by 4% for the three months ended September 30, 2016 as compared to the same period in 2015 primarily due to same market treatment growth (3%) and contributions from acquisitions (1%). At September 30, 2016, 187,611 patients (a 4% increase from September 30, 2015) were being treated in the 2,277 dialysis clinics that we own or operate in the North America Segment, compared to 181,230 patients treated in 2,205 dialysis clinics at September 30, 2015.

       In the U.S., the average revenue per treatment was $350 for the three months ended September 30, 2016 and $347 for the same period in 2015. The increase was mainly attributable to a favorable impact from a higher volume of dialysis treatments with commercial payors.

       Cost per treatment in the U.S. increased to $278 for the three months ended September 30, 2016 from $273 in the same period of 2015. This increase was largely driven by higher personnel expense and administrative costs, partially offset by a favorable impact from lower cost for health care supplies.

       Dialysis product revenue increased by 7% to $232 million for the three months ended September 30, 2016 as compared to $219 million in the same period in 2015. This was driven by higher sales of machines, dialyzers, renal pharmaceuticals and peritoneal dialysis products.

Operating Income

       Dialysis operating income increased to $505 million for the three months ended September 30, 2016 as compared to $482 million in the same period in 2015. Operating income margin decreased to 18.8% for the three months ended September 30, 2016 from 19.1% for the same period in 2015, due to higher personnel expense and a cost impact related to the vesting of long term incentive plan grants, partially offset by lower costs from health care supplies, a higher volume with commercial payors and increased income from equity method investees.

Delivered EBIT

       Dialysis delivered EBIT increased by 7% to $440 million for the three months ended September 30, 2016 from $413 million for the same period of 2015 mainly as the result of increased operating income coupled with decreased noncontrolling interests due to a change in how the effects of CMS cost recoveries are recognized in our joint ventures involving dialysis clinics.

Care Coordination

Revenue

       Care Coordination revenue increased by 29% to $618 million for the three months ended September 30, 2016 from $480 million for the same period of 2015. This increase was driven by increases in organic revenue growth (24%), contributions from acquisitions (4%) and effects of bad debt (1%).

13

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Operating Income

       Care Coordination operating income decreased to $31 million for the three months ended September 30, 2016 from $33 million for the same period of 2015. The operating income margin decreased to 5.0% for the three months ended September 30, 2016 from 6.8% mainly driven by increased costs for hospitalist and intensivist services due to infrastructure development and an unfavorable impact from endovascular and cardiovascular services, partially offset by ESCO shared savings revenue recognition.

Delivered EBIT

       Care Coordination delivered EBIT increased to $26 million for the three months ended September 30, 2016 from $22 million for the same period of 2015 mainly as the result of decreased noncontrolling interests effects, partially offset by decreased operating income.

Member Months Under Medical Cost Management

       Care Coordination's member months under medical cost management for the three months ended September 30, 2016 was 97,197 months as compared to 67,275 months for the same period of 2015. The increase in membership volume was largely due to furthered enrollment in our ESCOs coupled with the ESCOs initial inclusion in the fourth quarter of 2015 as well as growth in our sub-capitation and other shared savings arrangements and the continued contribution from MA-CSNPs which commenced in the first quarter of 2016, partially offset by a decrease in member months related to BPCI. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

Medical Cost Under Management

       Care Coordination's medical cost under management for the three months ended September 30, 2016 was $718 million as compared to $502 million for the same period of 2015. The increase in medical cost under management was attributable to the furthered enrollment in our ESCOs coupled with the ESCOs initial inclusion in the fourth quarter of 2015 as well as growth in our sub-capitation and other shared savings arrangements and the continued contribution from MA-CSNPs which commenced in the first quarter of 2016, partially offset by the decrease in BPCI member months noted above. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

Care Coordination Patient Encounters

       Care Coordination's patient encounters for the three months ended September 30, 2016 were 1,411,251 encounters and procedures as compared to 1,232,632 encounters and procedures for the three months ended September 30, 2015. The increase was driven by patient encounters and procedures provided by hospitalist and intensivist services, Fresenius Medical Care Rx Bone Mineral Metabolism ("Rx BMM") program, urgent care centers, vascular procedures as well as cardiovascular and endovascular services. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

14

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

New Care Coordination Activities

       In the second quarter of 2016, we expanded our Care Coordination activities with an investment in a physician practice which provides a professional fee capitation program for cardiology services. We will incorporate this new activity into our Care Coordination business metrics in the fourth quarter of 2016.

(1) For further information on Constant Exchange Rates, see "Non-U.S. GAAP Measures for Presentation – Constant Currency" below.

(2) Net of patient service bad debt provision.

(3) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

Revenue

       Total revenue for the EMEA Segment increased by 2% (4% increase at Constant Exchange Rates) to $675 million for the three months ended September 30, 2016 as compared to $659 million for the same period of 2015. Health care service revenue for the EMEA Segment increased by 8% (10% increase at Constant Exchange Rates) to $335 million during the three months ended September 30, 2016 as compared to $309 million for the same period of 2015. This is a result of contributions from acquisitions (8%) and same market treatment growth (4%), partially offset by the negative effect of exchange rate fluctuations (2%), decreases in organic revenue growth per treatment (1%) and the effect of closed or sold clinics (1%). Dialysis treatments increased by 9% for the three months ended September 30, 2016 over the same period in 2015 mainly due to contributions from acquisitions (6%) and same market treatment growth (4%), partially offset by the effect of closed or sold clinics (1%). As of September 30, 2016, we had 59,233 patients (10% increase from September 30, 2015) being treated at the 701 dialysis clinics that we own, operate or manage in the EMEA Segment compared to 53,887 patients treated at 648 clinics at September 30, 2015.

15

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

       Dialysis product revenue for the three months ended September 30, 2016 decreased by 3% (1% decrease at Constant Exchange Rates) to $340 million as compared to $350 million in the same period of 2015. The decrease at Constant Exchange Rates was driven by lower sales of renal pharmaceuticals, dialyzers, and peritoneal dialysis products, partially offset by higher sales of machines and bloodlines.

Operating Income

       Operating income decreased to $125 million for the three months ended September 30, 2016 as compared to $130 million for the same period in 2015. Operating income margin decreased to 18.5% for the three months ended September 30, 2016 from 19.7% for the same period in 2015 mainly due to the prior year impact from a gain from the sale of our European marketing rights for certain renal pharmaceuticals, an unfavorable impact from manufacturing costs and higher bad debt expense, partially offset by favorable foreign exchange effects.

Delivered EBIT

       Delivered EBIT decreased by 4% to $124 million for the three months ended September 30, 2016 as compared to $129 million for the same period in 2015 due to decreased operating income, partially offset by increased noncontrolling interests.

(1) For further information on Constant Exchange Rates, see "Non-U.S. GAAP Measures for Presentation – Constant Currency" below.

(2) Net of patient service bad debt provision.

(3) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

16

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Revenue

       Total revenue for the Asia-Pacific Segment increased by 13% (8% increase at Constant Exchange Rates) to $427 million for the three months ended September 30, 2016 as compared to $378 million for the same period of 2015. Health care service revenue for the Asia-Pacific Segment increased during the three months ended September 30, 2016 by 15% (3% increase at Constant Exchange Rates) to $192 million from $168 million in the same period of 2015. This increase is a result of the effect of exchange rate fluctuations (12%) and same market treatment growth (4%), partially offset by the effect of closed or sold clinics (1%). Dialysis treatments increased by 5% for the three months ended September 30, 2016 over the same period in 2015 mainly due to same market treatment growth (4%) and acquisitions (2%), partially offset by the effect of closed or sold clinics (1%). As of September 30, 2016, we had 29,358 patients (a 13% increase from September 30, 2015) being treated at the 369 dialysis clinics that we own, operate or manage in the Asia-Pacific Segment compared to 25,995 patients treated at 320 clinics at September 30, 2015.

       Dialysis product revenue for the three months ended September 30, 2016 increased by 11% (12% increase at Constant Exchange Rates) to $235 million compared to $210 million in the same period of 2015. The increase at Constant Exchange Rates was driven by increased sales of products for acute care, machines, dialyzers, bloodlines, peritoneal dialysis products and hemodialysis solutions and concentrates.

Operating Income

       Operating income increased by 25% to $85 million for the three months ended September 30, 2016 as compared to $68 million for the same period in 2015. Operating income margin increased to 19.8% for the three months ended September 30, 2016 compared to 17.9% in the same period of 2015 due to a positive impact from business growth and favorable foreign exchange effects.

Delivered EBIT

       Delivered EBIT increased by 27% to $83 million for the three months ended September 30, 2016 as compared to $65 million for the same period in 2015 due to increased operating income.

17

Table of Contents

(1) For further information on Constant Exchange Rates, see "Non-U.S. GAAP Measures for Presentation – Constant Currency" below.

(2) Net of patient service bad debt provision.

(3) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

Revenue

       Total revenue for the Latin America Segment increased by 9% (27% increase at Constant Exchange Rates) to $192 million for the three months ended September 30, 2016 as compared to $176 million for the same period of 2015. Health care service revenue for the Latin America Segment increased by 6% (31% increase at Constant Exchange Rates) during the three months ended September 30, 2016 to $139 million as compared to $131 million in the same period of 2015. This increase is a result of increases in organic revenue per treatment primarily driven by a retrospective reimbursement rate increase (30%), contributions from acquisitions (3%) and growth in same market treatments (2%), partially offset by the negative effect of exchange rate fluctuations (25%) and the effect of closed or sold clinics (4%). Dialysis treatments increased by 1% for the three months ended September 30, 2016 over the same period in 2015 mainly due to contributions from acquisitions (3%) and same market treatment growth (2%), partially offset by the effect of closed or sold clinics (4%). As of September 30, 2016, we had 30,164 patients being treated at the 232 dialysis clinics that we own, operate or manage in the Latin America Segment compared to 30,117 patients treated at 229 clinics at September 30, 2015.

       Dialysis product revenue for the three months ended September 30, 2016 increased by 19% (18% increase at Constant Exchange Rates) to $53 million compared to $45 million in the same period of 2015. The 18% increase at Constant Exchange Rates was mainly driven by higher sales of dialyzers, hemodialysis solutions and concentrates and bloodlines, partially offset by lower sales of peritoneal dialysis products and machines.

18

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Operating Income

       Operating income increased to $20 million for the three months ended September 30, 2016 as compared to $(8) million for the same period in 2015. Operating income margin increased to 10.5% for the three months ended September 30, 2016 from (4.7%) for the same period in 2015 mainly due to the prior year loss from the divestment of the dialysis service business in Venezuela and the impact from higher revenue in the region, partially offset by unfavorable foreign exchange effects and higher costs mainly related to inflation.

Delivered EBIT

       Delivered EBIT increased to $20 million for the three months ended September 30, 2016 as compared to $(8) million for the same period in 2015 due to increased operating income.

Nine months ended September 30, 2016 compared to nine months ended September 30, 2015

(1) For further information on Constant Exchange Rates, see "Non-U.S. GAAP Measures for Presentation – Constant Currency" below.

(2) Net of patient service bad debt provision.

(3) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

19

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

       Total Revenue increased by 7% (8% increase at Constant Exchange Rates) to $13,224 million for the nine months ended September 30, 2016 from $12,390 million in the same period of 2015 due to increases in Health Care revenue and dialysis product revenue.

       Health Care revenue increased by 8% to $10,720 million (9% increase at Constant Exchange Rates) for the nine months ended September 30, 2016 from $9,929 million in the same period of 2015, mainly due to increases in organic revenue per treatment (4%), growth in same market treatments (3%), contributions from acquisitions (2%) and an increase in dialysis days (1%), partially offset by the negative effect of exchange rate fluctuations (1%)and the effect of closed or sold clinics (1%).

       Dialysis treatments increased by 4% for the nine months ended September 30, 2016 as compared to the same period in 2015. The increase is due to same market treatment growth (3%) and contributions from acquisitions (2%), partially offset by the effect of closed or sold clinics (1%).

       Dialysis product revenue increased by 2% (4% increase at Constant Exchange Rates) to $2,504 million as compared to $2,461 million in the same period of 2015. The increase at Constant Exchange Rates was driven by increased sales of dialyzers, machines, bloodlines, products for acute care treatments, hemodialysis solutions and concentrates and peritoneal dialysis products, partially offset by lower sales of renal pharmaceuticals.

       The increase in gross profit margin to 31.7% from 31.2% primarily reflects increases in the North America Segment and the Asia-Pacific Segment. The increase in the North America Segment was mainly due to lower costs for health care supplies and a higher volume of dialysis treatments with commercial payors, partially offset by higher personnel expense related to dialysis services and an unfavorable impact from Care Coordination services. The increase in the Asia-Pacific Segment was driven by business growth and favorable foreign exchange effects.

       Selling, general and administrative ("SG&A") expenses increased to $2,278 million in the nine months ended September 30, 2016 from $ 2,120 million in the same period of 2015. SG&A expenses as a percentage of sales increased to 17.2% for the nine months ended September 30, 2016 in comparison with 17.1% in the same period of 2015 due to increases in the Asia-Pacific Segment, Corporate and the EMEA Segment, partially offset by a decrease in the Latin America Segment and a favorable impact of varying margins across our four reporting segments. The increase in the Asia-Pacific Segment was mainly due to increased costs related to further sales development, costs associated with changes in the Management Board and unfavorable foreign exchange effects. The increase at Corporate was primarily driven by higher overhead costs for manufacturing. The increase in the EMEA Segment was driven by the prior year impact from a gain from the sale of our European marketing rights for certain renal pharmaceuticals and higher bad debt expense, partially offset by the impact from higher sales. The decrease in the Latin America Segment was mainly due to the prior year loss related to the divestment of the dialysis service business in Venezuela as well as the impact from higher sales, partially offset by higher costs related to inflation.

       Research and development ("R&D") expenses increased by 20% to $120 million for the nine months ended September 30, 2016 from $100 million for the same period of 2015 driven by higher personnel expense and project costs related to an expansion of our project portfolio.

       Income from equity method investees increased to $61 million for the nine months ended September 30, 2016 from $22 million for the same period of 2015. This increase is primarily related to

20

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

higher income from the Vifor Fresenius Medical Care Renal Pharma Ltd. joint venture due to increased revenue resulting from the expansion of its product portfolio.

       Operating income increased to $1,851 million for the nine months ended September 30, 2016 from $1,665 million for the same period in 2015. Operating income margin increased to 14.0% for the nine months ended September 30, 2016 as compared to 13.4% for the same period in 2015 as a result of increased gross profit margin and income from equity method investees, partially offset by an increase in SG&A as a percentage of revenue.

       Delivered EBIT increased to $1,634 million for the nine months ended September 30, 2016 from $1,458 million for the same period in 2015 as a result of increased operating income, partially offset by increased noncontrolling interests driven by higher operating income of our joint ventures involving dialysis clinics.

       Interest expense decreased by 10% to $346 million for the nine months ended September 30, 2016 from $384 million for the same period in 2015 due to the lower impact of the valuation of the embedded derivative related to the equity-neutral convertible bonds issued in September 2014 and the related call option on our shares as well as due to a reduction in our overall debt level. Interest income decreased by 52% to $38 million for the nine months ended September 30, 2016 as compared to $80 million for the same period in 2015 due to the lower impact of the valuation of the derivative embedded in the convertible debt and the related call option on our shares as well as the repayment of interest bearing notes receivables in the fourth quarter of 2015.

       Income tax expense increased to $471 million for the nine months ended September 30, 2016 as compared to $441 million for the same period in 2015. The effective tax rate decreased to 30.5% from 32.4% for the same period of 2015 mainly driven by lower tax expense as a result of released tax liabilities in the third quarter of 2016 due to tax audit settlements with the tax authorities and a prior year impact from the non-tax deductible loss from the divestiture of our dialysis service business in Venezuela, partially offset by a lower portion of tax free income attributable to noncontrolling interests compared to income before taxes.

       Net income attributable to noncontrolling interests for the nine months ended September 30, 2016 increased to $217 million from $207 million for the same period of 2015 primarily driven by higher operating income of joint ventures with dialysis clinics, partially offset by decreased noncontrolling interest expense related to Care Coordination, both in the North America Segment.

       Net income attributable to shareholders of FMC-AG & Co. KGaA for the nine months ended September 30, 2016 increased by 20% to $855 million from $713 million for the same period in 2015 as a result of the combined effects of the items discussed above. Excluding the impacts of (i) the 2015 after tax loss, $26.9 million, from the divestiture of our dialysis service business in Venezuela and (ii) the 2015 realized portion of the after tax gain, $4.8 million, from the sale of our European marketing rights for certain renal pharmaceuticals to our joint venture, Vifor Fresenius Medical Care Renal Pharma, net income attributable to FMC KGaA increased by 16%.

       Basic earnings per share increased by 19% for the nine months ended September 30, 2016 to $2.80 as compared with $2.34 for the same period in 2015 primarily due to the increase in net income attributable to shareholders of FMC-AG & Co. KGaA described above. The average weighted number of shares outstanding for the period was approximately 305.6 million in 2016 (304.2 million in 2015).

21

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

       The following discussions pertain to the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment and the measures we use to manage these segments.

(1) Net of patient service bad debt provision.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income for each our reporting segments, see "Non-U.S. GAAP Measures for Presentation – Delivered EBIT" below.

(3) For further information on these metrics, please refer to the discussion below of our Care Coordination measures under "Care Coordination Business Metrics for Presentation."

(4) The 2016 metric may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

22

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Dialysis

Revenue

       Dialysis revenue increased for the nine months ended September 30, 2016 by 6% to $7,808 million from $7,348 million in the same period of 2015.

       Dialysis care revenue increased for the nine months ended September 30, 2016 by 6% to $7,134 million from $6,705 million in the same period of 2015. This increase was driven by same market treatment growth (3%), increases in organic revenue per treatment (2%), an increase in dialysis days (1%) and contributions from acquisitions (1%), partially offset by the effect of closed or sold clinics (1%).

       Dialysis treatments increased by 5% for the nine months ended September 30, 2016 as compared to the same period in 2015 primarily due to same market treatment growth (3%), an increase in dialysis days (1%) and contributions from acquisitions (1%).

       In the U.S., the average revenue per treatment was $350 for the nine months ended September 30, 2016 and $345 for the same period in 2015. The increase was mainly attributable to a higher volume of dialysis treatments with commercial payors.

       Cost per treatment in the U.S. decreased to $281 for the nine months ended September 30, 2016 from $282 in the same period of 2015. This decrease was largely driven by a favorable impact from lower cost for health care supplies, partially offset by higher personnel expense, rent expense and administration costs.

       Dialysis product revenue increased by 5% to $674 million for the nine months ended September 30, 2016 as compared to $643 million in the same period in 2015. This was driven by higher sales of machines, dialyzers and peritoneal dialysis products, partially offset by lower sales of renal pharmaceuticals.

Operating Income

       Dialysis operating income increased to $1,420 million for the nine months ended September 30, 2016 as compared to $1,199 million in the same period in 2015. Operating income margin increased to 18.2% for the nine months ended September 30, 2016 from 16.3% for the same period in 2015, due to lower costs from health care supplies, a higher volume with commercial payors, higher income from equity method investees and lower legal expenses, partially offset by higher personnel expense, and a cost impact related to the vesting of long term incentive plan grants.

Delivered EBIT

       Dialysis delivered EBIT increased by 19% to $1,232 million for the nine months ended September 30, 2016 from $1,033 million for the same period of 2015 mainly as the result of increased operating income, partially offset by increased noncontrolling interests driven by higher operating income of our joint ventures involving dialysis clinics.

23

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Care Coordination

Revenue

       Care Coordination revenue increased by 23% to $1,704 million for the nine months ended September 30, 2016 from $1,382 million for the same period of 2015. This increase was driven by increases in organic revenue growth (19%), contributions from acquisitions (3%) and effects of bad debt (1%).

Operating Income

       Care Coordination operating income decreased to $66 million for the nine months ended September 30, 2016 from $85 million for the same period of 2015. The operating income margin decreased to 3.9% for the nine months ended September 30, 2016 from 6.1% mainly driven by increased costs for hospitalist and intensivist services as well as physician practice services due to infrastructure development, partially offset by increased sales of pharmacy services.

Delivered EBIT

       Care Coordination delivered EBIT decreased to $44 million for the nine months ended September 30, 2016 from $52 million for the same period of 2015 mainly as the result of decreased operating income partially offset by decreased noncontrolling interests effects.

Member Months Under Medical Cost Management

       Care Coordination's member months under medical cost management for the nine months ended September 30, 2016 was 281,964 months as compared to 111,867 months for the same period of 2015. The increase in membership volume was largely attributable to BPCI development, furthered enrollment in our ESCOs coupled with the ESCOs initial inclusion in the fourth quarter of 2015, growth in sub-capitation and our other shared savings arrangements as well as the continued contribution from MA-CSNPs which commenced in the first quarter of 2016. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

Medical Cost Under Management

       Care Coordination's medical cost under management for the nine months ended September 30, 2016 was $2,036 million as compared to $965 million for the same period of 2015. The increase in medical cost under management was largely attributable to BPCI development, furthered enrollment in our ESCOs coupled with the ESCOs initial inclusion in the fourth quarter of 2015, growth in sub-capitation and our other shared savings arrangements as well as the continued contribution from MA-CSNPs which commenced in the first quarter of 2016. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

24

Table of Contents

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2016 and 2015

Care Coordination Patient Encounters

       Care Coordination's patient encounters for the nine months ended September 30, 2016 were 4,057,022 encounters and procedures as compared to 3,774,936 encounters and procedures for the nine months ended September 30, 2015. The increase was driven by patient encounters and procedures provided by hospitalist and intensivist services, Rx BMM program, urgent care centers, vascular procedures as well as cardiovascular and endovascular services. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

New Care Coordination Activities

       In the second quarter of 2016, we expanded our Care Coordination activities with an investment in a physician practice which provides a professional fee capitation program for cardiology services. We will incorporate this new activity into our Care Coordination business metrics in the fourth quarter of 2016.